Edited by Tamas Dalmay microRNAs (miRNAs) are small noncoding RNA molecules involved in the regulation of gene expression and play critical roles in human malignancies. Next-generation sequencing analysis of the MCF-7 breast cancer cell line overexpressing miR-335-5p and miR-335-3p demonstrated that the miRNA duplex repressed genes involved in the ERa signaling pathway, and enhanced resistance of MCF-7 cells to the growth inhibitory effects of tamoxifen. These data suggest that despite its conventional role in tumor suppression, the miR-335 transcript can also play an oncogenic role in promoting agonistic estrogen signaling in a cancerous setting.
. Endocrine resistance, attained through loss of either ERa expression or function, occurs through multiple mechanisms including methylation, promoter inhibition, and most recently microRNAs (miRNAs) regulation.
MicroRNAs are small noncoding RNA molecules involved in the regulation of gene expression at the level of translation. Conventional miRNA biogenesis pathways consist of one strand of a miRNA duplex preferentially selected for entry into RNA-induced silencing complex for gene silencing, while the other strand is degraded [7, 8] . There are many miRNAs which have been demonstrated to regulate ERa through miRNA binding to the 3 0 UTR of ERa mRNA and inducing downstream gene silencing [9] [10] [11] [12] . Previous studies demonstrate both conventionally believed tumor-suppressive and oncogenic miRNAs can target ERa, elucidating variable effects on the breast cancer phenotype and clinical prognosis. For example, miR-221/222 induces resistance to endocrine therapies and metastasis, and miR-206 induces an antiproliferative effect, despite elevated levels of miR-206 in ERa À breast cancer cell lines [12] [13] [14] . Further exploration of miRNA pathways is essential for understanding their physiological role and their implications associated with the regulation of breast cancer. Here, we describe the effects of miR-335, a conventional tumor-suppressive miRNA which targets ERa and alters the endocrine response in ERa + breast cancer cell lines.
Materials and methods

Cells and reagents
MCF-7 human breast cancer cell line was purchased from American Type Culture Collection (Manassas, VA, USA). The MCF-7-TR and MCF-7-FR cell lines were generated as previously described [15] . Cells lines were cultured as previously described [16] . Liquid nitrogen stocks were made upon receipt and maintained until the start of study. ERE-luciferase and/or qPCR for ERa and PGR were used to confirm MCF-7-sustained estrogen responsiveness. Morphology and doubling times were also recorded regularly to ensure maintenance of phenotype for all cell lines. Cells were used for no more than 6 months in culture. Cells were maintained in 10% FBS DMEM (Dulbecco's modified Eagle medium) as previously described [17] . MCF-7 parental cells were thawed at passage 65 and were not used past passage 80. MCF-7-miR-335 cell line was used at passage 9 to passage 18. ICI 182,780 was purchased from Tocris Bioscience (Avonmouth, Bristol, UK), 4hydroxy (4OH) tamoxifen was purchased from (Calbiochem, Damstadt, Germany), and 1 nM 17b-estradiol (E2) was purchased from Sigma (St. Louis, MO, USA).
Transfection of MCF-7 cell line
Parental MCF-7 cell line (passage 65) was stably transfected with pLEMIR-RFP-vector or pLEMIR-RFP-premiR-335 (GE Dharmacon, Lafayette, CO, USA) with Lipofectamine 2000 per manufacturer's protocol (Invitrogen, Grand Isles, NY, USA). Parental MCF-7 cells were grown in 100-mm dishes. Plasmid (5 lg) was added to 100 lL of serum-free opti-MEM followed by 15 lL Lipofectamine. After a 30-min incubation period, opti-MEM containing plasmid was added. The following day, pLEMIR-transfected cells were treated with 300 ngÁmL À1 puromycin.
Cells were grown in 10% DMEM and treated with 300 ngÁmL À1 puromycin (pLEMIR) every 2 days for 2 weeks. Colonies were pooled and verification of miR-335 overexpression was confirmed using qPCR. Stable pools of transfected cells were maintained in 10% DMEM as described above and were not used beyond passage 18.
Crystal violet assay
MCF-7-vector and MCF-7-miR-335 cells were grown in 5% phenol-free DMEM for 24 h and then plated in 24-well plates (7500 cells per well) for 24 h prior to pretreatment with 100 nM ICI 182,780 or 100 nM 4OH tamoxifen followed by a one-time treatment with 1 nM E2 or DMSO. After 72 h, cells were washed once with PBS and fixed and stained using 0.1% crystal violet (in 20% methanol) for 10 min. Cells were washed with water and lysed with 1% SDS. Absorbance at wavelength 570 was determined using a Gene5 plate reader (BioTek, Winooski, VT, USA). To account for variance in plating and cell adhesion between cell lines, each cell line was normalized to its respective DMSO-treated group designated as 100.
RNA extraction and quantitative real-time RT-PCR
MCF-7-pLEMIR-vector and MCF-7-pLEMIR-MCF7-335 cells were harvested for total RNA extraction using Qiagen RNeasy (Qiagen, Valencia, CA, USA). Quantity and quality of the RNA was determined by absorbance at 260 and 280 nm using the NanoDrop ND-1000. Total RNA (1 lg) was reverse-transcribed using the iScript kit (BioRad Laboratories, Hercules, CA, USA) and qPCR was performed using SYBR-green and 300 ng cDNA (Bio-Rad Laboratories). b-Actin, PGR, ERa, and ERa-36 genes were amplified n = 3. ERa forward GGCATGGTGGAGATCTTC GA, ERa reverse CCTCTCCCTGCAGATTCATCA, ERa-36 forward CAAGTGGTTTCCTCGTGTCTAAAGC, ERa-36 reverse TGTTGAGTGTTGGTTCCAGG, PGR forward TACCCGCCCTATCTCAACTACC, PGR reverse TGCTTCATCCCCACAGATTAAACA, b-actin forward TGAGCGCGGCTACAGCTT, b-actin reverse CCTTAAT GTCACACACGATT. Data were analyzed by comparing relative target gene expression to b-actin. Relative gene expression was analyzed using 2 ÀDDCt method. qPCR for miRNA was as follows, total RNA was extracted using the Qiagen miRNeasy kit (Qiagen) as per manufacturers protocol and small RNA fraction was not selected for. About 1.5 lg of total RNA was reverse transcribed using the Qiagen miScript II kit and qPCR was performed using miScript SYBR green and primers for pre-mir-335, miR-335-5p, miR-335-3p, and U6 purchased from Qiagen. Normalization was to U6.
RNA-sequencing analysis
RNA-sequencing was performed as in our previously described methods for read preparation, repeat masking, and read mapping. [18] . Edge R software was used to determine differential gene expression [version 2.6.0] by inputting the raw gene counts [19] . The estimatecommonDisp and estimateTagwiseDisp methods were used to estimate dispersion [20, 21] and a prior n value = 10 was used for running estimateTagwiseDisp. Pathway analysis was performed using the curated database provided by NCI-Nature Pathway Interaction Database (analysis performed 2014) [22] .
Data sources
The Cancer Genome Atlas (TCGA) research network breast cancer gene expression data (RNA-seq deep sequencing data) were viewed through the University California Santa Cruz (UCSC) Cancer Genomics Browser [23] [24] [25] .
The breast invasive carcinoma TCGA data set (total of n = 1032 tumor samples) was used and analyzed for gene expression aligned through the IlluminaHiSeq system (Illumina, San Diego, CA, USA). Gene signatures were based on receptor status (ERa, PGR, and HER2) and molecular subtype (Luminal A, Luminal B, HER2-enriched, and basal-like). MicroRNAs can directly target ERa and induce an endocrine-resistant advanced phenotype. miR-335-5p, while conventionally described as a tumor suppressor, represses ERa in breast cancer cells and is induced by estrogen stimulation, suggesting it may be involved in altered estrogen signaling [26] . To gain greater insight into the effects of the miR-335 transcript on estrogen signaling we performed qRT-PCR to determine basal expression levels of pre-miR-335, miR-335-5p, and miR-335-3p across a series of breast cancer cell lines (ERa + and ER À ). miR-335-3p was included in our analysis due to recent evidence suggesting a functional role for both strands of the miRNA duplex [27] . qRT-PCR results demonstrated that both miR-335-5p and miR-335-3p were robustly expressed across all breast cancer cell lines regardless of receptor status, with expression at physiologically relevant levels (Fig. 1A) . There was no correlation with pre-miR-335, miR-335-5p, or miR-335-3p to a specific breast cancer subtype. To determine if the observed enhanced expression of miR-335 in cell lines translated to a similar expression in clinical breast tumor samples, TCGA was used to determine expression levels of miR-335 across subsets of breast tumor samples. miR-335 was observed to have overall higher expression levels in normal tissue compared to that of tumor tissue (Fig. 1B) , consistent with previous studies identifying miR-335 as a tumor suppressor. However, in evaluation of clinical tumor samples, miR-335 was observed to be expressed in all tumor subtypes with no indication of a subtype-specific expression mechanism (Fig. 1C) .
Western blot
miR-335-3p and miR-335-5p dual target mRNAs
Since both strands of the miR-335 duplex were observed to be expressed across breast cancer cell lines without apparent correlation with clinical tumor subtypes, we next determined the effects of forced expression of the miR-335 transcript on an ERa + breast cancer cell line. The parental MCF-7 cell line was stably transfected with a pre-miR-335 expression vector, and qPCR was used to confirm overexpression of both miR-335-5p and miR-335-3p in the MCF-7-miR-335 cell line ( Fig. 2A) . Next generation sequencing was performed on the MCF-7-miR-335 cell line and vector transfected cells to determine the overall changes in miR-335-induced gene expression. As viewed in Integrative Genomics Viewer (IGV), miR-335-5p and miR-335-3p overexpression was observed in the MCF-7-miR-335 cell line but not in the -vector cell line (Fig. 2B) . Analysis of the miR-335-5p and miR-335-3p transcript in IGV demonstrated that the miR-335 transcript was processed without alterations on either the 3 0 or 5 0 ends. Our results suggest that conventional miR-335 duplex strands, miR-335-5p and miR-335-3p, are expressed and that normal miRNA/mRNA targeting should occur.
Given that miR-335-5p and miR-335-3p were both overexpressed in our MCF-7-miR-335 cell line and contained intact 3-p and 5-p miRNAs, we next determined if the function of one miRNA strand was more prominent than the other. To evaluate this, we profiled all significantly down-regulated genes from our deep sequencing analysis for seed sites to either miR-335-5p or miR-335-3p independently. Seed sites were determined through our in-house program, SEEDFINDER [28] . Both miRNA strands had similar numbers of overall genes which contained a 3 0 UTR seed site and similar percentages of gene alteration. A total of 2799 genes contained a seed site for both miR-335-5p and miR-335-3p, and of these genes only 38 were observed to be significantly repressed in our RNA sequencing (FDR < 0.05) (Table S1 ). Furthermore, 32 and 62 genes were observed to be significantly repressed that contained only seed sites for miR-335-5p or miR-335-3p, respectively (Fig. 2C) . Since both miR-335-5p and miR-335-3p exhibited similar numbers of repressed genes, we next performed pathway analysis for significantly down-regulated genes that contained a seed site for either miR-335-5p or miR-335-3p. Pathway analysis of genes repressed by miR-335-5p and miR-335-3p suggested that there was an overlap in target genes as well as pathways (Fig. 3A,B) . Furthermore, pathway analysis demonstrated that based on repressed gene sets, both miR-335-5p and miR-335-3p had the potential to alter CDH1 stability, RAC1 activity, PDGFR signaling, and ERa signaling networks. To determine the global effect of the miR-335 construct on the MCF-7 breast cancer phenotype, we next determined the overall top down-regulated pathways as observed in our RNA sequencing, irrespective of genes possessing a miR-335-5p or miR-335-3p seed site (Fig. 3C) . Our results indicated that the ERa signaling pathway was one of the top down-regulated pathways.
miR-335-3p and miR-335-5p regulate ERa mRNA expression
To further investigate the ERa signaling network, we used qPCR analysis to evaluate hormone receptor expression of both ERa and PGR in our MCF-7-miR-335 cell line. Results demonstrated that both ERa and PGR were significantly decreased in the MCF-7-miR-335 cell line compared to the -vector (Fig. 4A) , in accordance with previous studies [26] . To investigate the effects of the loss of ERa on cellular response to endocrine therapies, the MCF-7-miR-335 cell line was cell line, ICI 182,780 had no effect (Fig. 4B) . The loss of inhibition of tamoxifen in the E2/tamoxifen-treated group has been observed in previous studies [29] . These data suggest that altered estrogen signaling due to miR-335 resulted in induced agonistic activity of tamoxifen.
To determine if the miR-335 transcript may be facilitating endocrine resistance, we next profiled the expression of pre-miR-335, miR-335-5p, and miR-335-3p in both MCF-7 tamoxifen-resistant and ICI 182,780-resistant cell lines, MCF-7-TR and MCF-7-FR, respectively. Evaluation of the miR-335 transcript expression revealed an increase in pre-miR-335 expression in MCF-7-TR cells compared to the parental MCF-7 cell line, in addition to a significant repression of miR-335-3p in both endocrine-resistant cell lines. There was no observed change in miR-335-5p expression in either endocrine-resistant cell lines compared to the parental MCF-7 cells (Fig. 4C ). Since there was no correlation with enhanced miR-335 expression and endocrine-resistant cell lines, we next determined a mechanism for the loss of response to endocrine therapy in our MCF-7-miR-335 cell line. While ERa contained seed sites to both miR-335-5p and miR-335-3p, it was not observed to be significantly repressed in our next-generation sequencing (Table S1 ). However, ERa was significantly repressed by qPCR and has been previously reported to be a direct target of miR-335. To further evaluate these discrepancies and to fully understand the ERa/miR-335 interplay, we analyzed the 3 0 UTR of ERa for miR-335-5p and miR-335-3p seed sites using the UCSC Genome Browser and our next-generation sequencing data. Although our results demonstrated ERa repression in the MCF-7-miR-335 cell line compared to the -vector, there were differences observed in the expression levels of ERa across the exons with severely repressed expression toward the 3 0 UTR (Fig. 5A) . To further investigate, we analyzed truncated isoforms of ERa which do not contain a 3 0 UTR as conventional ERa isoforms, and thus are not targeted by the same miRNAs. ERa-36 is an isoform which does not possess a 3 0 UTR with miR-335-5p or miR-335-3p seed sites. Additionally, the ERa-36 variant is known to activate rapid estrogen signaling pathways through MAPK and PI3K/AKT, inducing endocrine resistance [4] . qPCR demonstrated that ERa-36 expression levels were significantly increased in the MCF-7-miR-335 cell line compared to the control vector (Fig. 5B) and unlike other ERa variants, ERa-36 has a severely truncated 3 0 UTR that does not contain a miR-335 seed site (Table S2) . Furthermore, MCF-7-TR and MCF-7-FR cell lines did not display significantly enhanced expression of ERa-36, which correlated with the lack of miR-335 change in these cell lines (Fig. 5C ). Full-length ERa is known to repress ERa-36 expression, so we next determined if loss of full-length ERa expression induced the observed enhanced expression of ERa-36 [30] . We used a truncated ERa without 3 0 UTR to negate effects of (Fig. 5D) . Western blot analysis for ERa and ERa-36 protein expression demonstrated decreased expression of both proteins in the MCF-7-miR-335 cell line versus vector (Fig. 6 ). Given that we observed no enhancement of ERa-36 protein expression in the MCF-7-miR-335 cell line, we next evaluated activity in MAPKs and growth factormediated genes involved in endocrine resistance pathways. As shown in Table 1 , we analyzed MAPK and growth factor-mediated genes in our MCF-7-miR-335 sequencing data and observed an increase in select MAPK-mediated pathways including p38, p42/44, ERK1/2, and JNK. These data suggest repression of ERa by miR-335 is not the mechanism driving ERa-36 expression and that growth factor-mediated resistance may be involved.
Discussion
Numerous miRNAs have been involved in acquired resistance to endocrine therapies, providing a novel platform for gene regulation that has yet to be been fully explored. Despite a strong correlation between expression of ERa and a favorable response to endocrine therapy, 40-50% of patients with ERa + breast cancer develop resistance or exhibit de novo resistance [40] , and patients with luminal B and ERa + /PGR À breast cancer exhibit a poor response to tamoxifen.
The underlying mechanism appears to be deregulation in ERa signaling pathways [2, 5] due to crosstalk of growth factor signaling pathways such as PI3K/AKT/ mTOR and epidermal growth factor receptor (EGFR) crosstalk with ERa signaling to enhance proproliferative ERa-regulated gene expression and suppression of PGR gene expression [2] . We explored miRNA regulatory pathways interfering with ERa expression and demonstrated a miRNA-induced mechanism for endocrine resistance. The forced expression of miR-335 repressed ERa expression in addition to PGR, the classically regulated ERa gene. Furthermore, we demonstrated that not all isoforms of ERa were equally repressed by miR-335, with preferential repression of ERa over the truncated ERa-36 variant observed in the MCF-7-miR-335 cell line. The preferential repression of ERa was associated with increased survival in the MCF-7-miR-335 cell line following cotreatment of E2 and tamoxifen. Additionally, MCF-7 cells which had acquired tamoxifen or ICI resistance did not demonstrate enhanced miR-335 transcript expression or ERa-36 expression. These differences may represent fundamental alterations in signaling between acquired endocrine resistance and de novo resistance. miR-335 is regulated by estrogen stimulation, which suggests a feedback mechanism for the miR-335/ERa axis and a potential mechanism for endocrine resistance. Future studies may be warranted in the investigation of miRNAs such as miR-335 and de novo resistance. Although we did not observe increased protein expression of ERa-36 in the MCF-7-miR-335 cell line, we suspect increased MAPK expression may be an another mechanism leading to endocrine resistance. Overexpression and activation of growth factor HER2 has been shown to regulate ERa-36 expression through increased AP1 activation [41] . Additionally, activation of growth factor receptors, such as EGFR and IGF-1R, has been shown to drive proliferation and survival through activation of MAPK signaling pathways in endocrine-resistant breast cancers [42] . The role of miRNAs associated with endocrine resistance has been explored through the differential expression of miRNAs in tamoxifen-resistant cells [12] [13] [14] 43, 44] . Enhanced understanding of resistances to current therapies would elucidate novel methods for intervention. miRNAs that inhibit ERa such as miR-221/222 are strongly associated with resistance to tamoxifen [13, 14] and fulvestrant in basal-like breast cancer [45] . Differential miRNA expression between endocrine-resistant and -sensitive breast cancer cells has also been demonstrated [46] . In another tamoxifen-resistant cell model, miR-375 was identified as one of the top repressed miRNAs, and re-expression of miR-375 resulted in reversal of the tamoxifen-resistant phenotype [44] . miR-342 was also repressed in tamoxifen-resistant cell lines and believed to target genes associated with cell death and cell cycle [43] . While miR-335 has conventionally been described as tumor suppressive, our data demonstrated agonistic estrogen signaling and enhanced proliferation following combined treatment with E2 and tamoxifen. Additionally, TCGA-sequencing data demonstrated that despite high expression levels in normal tissue versus breast tumor tissue, miR-335 expression was not correlated with molecular subtype. This was further confirmed in vitro through our analysis of breast cancer cell lines with miR-335-5p, miR-335-3p, and pre-miR-335 expressed uniformly at robust levels across all subtypes. Our results suggest that miRNAs can have both tumor suppressive and oncogenic functions depending on the cellular system. While miR-335 has been conventionally characterized as tumor suppressive in normal/ nondiseased tissue, it can promote cancer drug resistance in estrogen-responsive tumors. Furthermore, our research demonstrates that miRNA function is dictated in a cell type-specific manner and dependent on the cellular transcriptome.
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